Selected research
Market Structure
Global Acute Agitation and Aggression Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Acute Agitation and Aggression Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Acute Agitation and Aggression Therapeutics include Johnson & Johnson, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Otsuka Holdings, Ono Pharmaceutical, H. Lundbeck A/S and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Acute Agitation and Aggression Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Acute Agitation and Aggression Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Acute Agitation and Aggression Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Acute Agitation and Aggression Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Acute Agitation and Aggression Therapeutics Segment by Company
Johnson & Johnson
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Otsuka Holdings
Ono Pharmaceutical
H. Lundbeck A/S
Bristol-Myers Squibb
Acute Agitation and Aggression Therapeutics Segment by Type
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Application
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Agitation and Aggression Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Agitation and Aggression Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Agitation and Aggression Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Acute Agitation and Aggression Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Agitation and Aggression Therapeutics industry.
Chapter 3: Detailed analysis of Acute Agitation and Aggression Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Agitation and Aggression Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Intramuscular Injection
- Others
Applications
- Oral
- Intramuscular Injection
- Others
Companies covered
- Johnson & Johnson
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Otsuka Holdings
- Ono Pharmaceutical
- H. Lundbeck A/S
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Acute Agitation and Aggression Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Intramuscular Injection
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Acute Agitation and Aggression Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Oral
- 1.3.3 Intramuscular Injection
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Acute Agitation and Aggression Therapeutics Growth Trends by Region
- 1.5.1 Global Acute Agitation and Aggression Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Acute Agitation and Aggression Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Acute Agitation and Aggression Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Acute Agitation and Aggression Therapeutics Market Dynamics
- 2.1 Acute Agitation and Aggression Therapeutics Industry Trends
- 2.2 Acute Agitation and Aggression Therapeutics Industry Drivers
- 2.3 Acute Agitation and Aggression Therapeutics Industry Opportunities and Challenges
- 2.4 Acute Agitation and Aggression Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Acute Agitation and Aggression Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Acute Agitation and Aggression Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Acute Agitation and Aggression Therapeutics Key Company Head office and Area Served
- 3.4 Global Acute Agitation and Aggression Therapeutics Company, Product Type & Application
- 3.5 Global Acute Agitation and Aggression Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Acute Agitation and Aggression Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Acute Agitation and Aggression Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Acute Agitation and Aggression Therapeutics Tier 1, Tier 2, and Tier 3
4 Acute Agitation and Aggression Therapeutics Market by Type
- 4.1 Global Acute Agitation and Aggression Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Acute Agitation and Aggression Therapeutics Market Size Share by Type (2021-2032)
5 Acute Agitation and Aggression Therapeutics Market by Application
- 5.1 Global Acute Agitation and Aggression Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Acute Agitation and Aggression Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Johnson & Johnson Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Eli Lilly and Company
- 6.2.1 Eli Lilly and Company Company Information
- 6.2.2 Eli Lilly and Company Business Overview
- 6.2.3 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.2.5 Eli Lilly and Company Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Pfizer Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 Otsuka Holdings
- 6.5.1 Otsuka Holdings Company Information
- 6.5.2 Otsuka Holdings Business Overview
- 6.5.3 Otsuka Holdings Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Otsuka Holdings Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.5.5 Otsuka Holdings Recent Developments
- 6.6 Ono Pharmaceutical
- 6.6.1 Ono Pharmaceutical Company Information
- 6.6.2 Ono Pharmaceutical Business Overview
- 6.6.3 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.6.5 Ono Pharmaceutical Recent Developments
- 6.7 H. Lundbeck A/S
- 6.7.1 H. Lundbeck A/S Company Information
- 6.7.2 H. Lundbeck A/S Business Overview
- 6.7.3 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.7.5 H. Lundbeck A/S Recent Developments
- 6.8 Bristol-Myers Squibb
- 6.8.1 Bristol-Myers Squibb Company Information
- 6.8.2 Bristol-Myers Squibb Business Overview
- 6.8.3 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.8.5 Bristol-Myers Squibb Recent Developments
7 North America
- 7.1 North America Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 7.2 North America Acute Agitation and Aggression Therapeutics Market Size by Type
- 7.2.1 North America Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Acute Agitation and Aggression Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Acute Agitation and Aggression Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Acute Agitation and Aggression Therapeutics Market Size by Application
- 7.3.1 North America Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Acute Agitation and Aggression Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Acute Agitation and Aggression Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Acute Agitation and Aggression Therapeutics Market Size by Country
- 7.4.1 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Acute Agitation and Aggression Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 8.2 Europe Acute Agitation and Aggression Therapeutics Market Size by Type
- 8.2.1 Europe Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Acute Agitation and Aggression Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Acute Agitation and Aggression Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Acute Agitation and Aggression Therapeutics Market Size by Application
- 8.3.1 Europe Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Acute Agitation and Aggression Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Acute Agitation and Aggression Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Acute Agitation and Aggression Therapeutics Market Size by Country
- 8.4.1 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Acute Agitation and Aggression Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 9.2 China Acute Agitation and Aggression Therapeutics Market Size by Type
- 9.2.1 China Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Acute Agitation and Aggression Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Acute Agitation and Aggression Therapeutics Market Share by Type (2021-2032)
- 9.3 China Acute Agitation and Aggression Therapeutics Market Size by Application
- 9.3.1 China Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Acute Agitation and Aggression Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Acute Agitation and Aggression Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 10.2 Asia Acute Agitation and Aggression Therapeutics Market Size by Type
- 10.2.1 Asia Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Acute Agitation and Aggression Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Acute Agitation and Aggression Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Acute Agitation and Aggression Therapeutics Market Size by Application
- 10.3.1 Asia Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Acute Agitation and Aggression Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Acute Agitation and Aggression Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Acute Agitation and Aggression Therapeutics Market Size by Country
- 10.4.1 Asia Acute Agitation and Aggression Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Acute Agitation and Aggression Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Acute Agitation and Aggression Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst